Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Ra… (NCT05314725) | Clinical Trial Compass
UnknownPhase 2
Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial
24 participantsStarted 2022-06-01
Plain-language summary
The aim of the study is to investigate the effect of an SGLT-2 inhibitor on postoperative hyperglycemia after acute abdominal surgery in patients without diabetes
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* \- Admitted to the ward after acute abdominal surgery (ASAP patient at Slagelse Hospital, OMEGA patient at Zealand University Hospital)
* At least two independent measurements of blood glucose above 7.7mmol/l within the first 48 hours after surgery
* Age of 18 to 85
* Must be able to understand and sign informed content
Exclusion Criteria:
* Patients diagnosed with diabetes mellitus
* Impaired kidney function (eGFR \< 45mL/min)
* Severe liver disease (defined as transaminases above X 3 normal levels)
* Acute pancreatitis within the last two months or a history of chronic pancreatitis
* Participation in another pharmacological intervention trial
* Predictable poor compliance (for instance mentally impaired)
* Pregnancy or lactation (fertile women must have a negative serum or urine pregnancy test to participate)
* Allergy to study medication
What they're measuring
1
time in range
Timeframe: from inclusion until 10 days after (or when the patient leaves the hospital)